TAMPA, FL / ACCESSWIRE / July 31, 2023 / TRxADE HEALTH INC. (NASDAQ:MEDS), is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., will release financial results for the second quarter 2023, after market close on August 14, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.
In addition, management will host a conference call on Monday, August 14th, 2023, at 6:00 p.m. Eastern time to discuss TRxADE HEALTH’s second quarter 2023 financial results. The call will conclude with a Q&A from participants. To participate, please use the following information:
Q2 2023 Conference Call and Webcast
Date: Monday, August 14, 2023
Time: 6:00 p.m. Eastern time
U.S. Dial-in: 1-877-425-9470
International Dial-in: 1-201-389-0878
Webcast: https://callme.viavid.com/viavid/?callme=true&passcode=13711397&h=true&info=company&r=true&B=6 – Participants can use Guest dial-in #s above and be answered by an operator
Please dial in at least 10 minutes before the start of the call to ensure timely participation.
A playback of the call will be available through September 14, 2023. To listen, call 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally and enter replay pin number 13740435. A webcast will also be available for 30 days on the IR section of the Trxade Group website or by clicking the webcast link above.
About TRxADE HEALTH, INC.
TRxADE HEALTH (NASDAQ:MEDS) is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S. The Company operates the TRxADE drug procurement marketplace serving approximately 14,500+ members nationwide, fostering price transparency and under the Bonum Health brand, offering patient centric telehealth services. For more information on TRxADE HEALTH, please visit the Company’s IR website at investors.trxadegroup.com.
Investor Relations:
IR@trxade.com
Investors.trxadegroup.com
SOURCE: TRxADE HEALTH, Inc.
View source version on accesswire.com:
https://www.accesswire.com/771201/TRxADE-HEALTH-INC-to-Report-Q2-2023-Financial-Results-on-Monday-August-14th-at-600-pm-Eastern-Time
CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…
Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…
Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…
Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…
Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…
Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a…